Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas

Michael Glantz, Marc Chamberlain, Qin Liu, N. Scott Litofsky, Lawrence D. Recht

Research output: Contribution to journalArticle

123 Citations (Scopus)

Abstract

BACKGROUND. The optimal treatment for elderly patients (defined as patients 70 years of age or older) with malignant gliomas (MG) remains controversial. Some physicians advocate withholding therapy following diagnosis based on the observation that elderly patients do not tolerate adjuvant radiotherapy. The availability of temozolomide (TMZ), a new alkylating agent with antiglioma efficacy, offers another potential therapeutic option for these patients. The drug can be administered orally at home with minimal morbidity. METHODS. The authors retrospectively reviewed a cohort of 86 consecutive elderly MG patients from three institutions, 32 of whom received monthly TMZ in lieu of radiation. RESULTS. Initial Karnofsky performance score was the only predictor of survival in this cohort. No difference in survival was noted between these two groups. Toxicity was minimal in the chemotherapy-treated group and a higher percentage of patients receiving chemotherapy died at home. CONCLUSIONS. The authors concluded that TMZ is as effective as irradiation as a treatment of elderly patients with MG. It is an alternative and, perhaps, a superior therapeutic option to irradiation, based on its ease of administration and low morbidity.

Original languageEnglish (US)
Pages (from-to)2262-2266
Number of pages5
JournalCancer
Volume97
Issue number9
DOIs
StatePublished - May 1 2003

Fingerprint

temozolomide
Glioma
Morbidity
Therapeutics
Drug Therapy
Adjuvant Radiotherapy
Survival
Alkylating Agents

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Glantz, Michael ; Chamberlain, Marc ; Liu, Qin ; Litofsky, N. Scott ; Recht, Lawrence D. / Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas. In: Cancer. 2003 ; Vol. 97, No. 9. pp. 2262-2266.
@article{c857e4a6a2fd4af89c873a5cbbe094cd,
title = "Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas",
abstract = "BACKGROUND. The optimal treatment for elderly patients (defined as patients 70 years of age or older) with malignant gliomas (MG) remains controversial. Some physicians advocate withholding therapy following diagnosis based on the observation that elderly patients do not tolerate adjuvant radiotherapy. The availability of temozolomide (TMZ), a new alkylating agent with antiglioma efficacy, offers another potential therapeutic option for these patients. The drug can be administered orally at home with minimal morbidity. METHODS. The authors retrospectively reviewed a cohort of 86 consecutive elderly MG patients from three institutions, 32 of whom received monthly TMZ in lieu of radiation. RESULTS. Initial Karnofsky performance score was the only predictor of survival in this cohort. No difference in survival was noted between these two groups. Toxicity was minimal in the chemotherapy-treated group and a higher percentage of patients receiving chemotherapy died at home. CONCLUSIONS. The authors concluded that TMZ is as effective as irradiation as a treatment of elderly patients with MG. It is an alternative and, perhaps, a superior therapeutic option to irradiation, based on its ease of administration and low morbidity.",
author = "Michael Glantz and Marc Chamberlain and Qin Liu and Litofsky, {N. Scott} and Recht, {Lawrence D.}",
year = "2003",
month = "5",
day = "1",
doi = "10.1002/cncr.11323",
language = "English (US)",
volume = "97",
pages = "2262--2266",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "9",

}

Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas. / Glantz, Michael; Chamberlain, Marc; Liu, Qin; Litofsky, N. Scott; Recht, Lawrence D.

In: Cancer, Vol. 97, No. 9, 01.05.2003, p. 2262-2266.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas

AU - Glantz, Michael

AU - Chamberlain, Marc

AU - Liu, Qin

AU - Litofsky, N. Scott

AU - Recht, Lawrence D.

PY - 2003/5/1

Y1 - 2003/5/1

N2 - BACKGROUND. The optimal treatment for elderly patients (defined as patients 70 years of age or older) with malignant gliomas (MG) remains controversial. Some physicians advocate withholding therapy following diagnosis based on the observation that elderly patients do not tolerate adjuvant radiotherapy. The availability of temozolomide (TMZ), a new alkylating agent with antiglioma efficacy, offers another potential therapeutic option for these patients. The drug can be administered orally at home with minimal morbidity. METHODS. The authors retrospectively reviewed a cohort of 86 consecutive elderly MG patients from three institutions, 32 of whom received monthly TMZ in lieu of radiation. RESULTS. Initial Karnofsky performance score was the only predictor of survival in this cohort. No difference in survival was noted between these two groups. Toxicity was minimal in the chemotherapy-treated group and a higher percentage of patients receiving chemotherapy died at home. CONCLUSIONS. The authors concluded that TMZ is as effective as irradiation as a treatment of elderly patients with MG. It is an alternative and, perhaps, a superior therapeutic option to irradiation, based on its ease of administration and low morbidity.

AB - BACKGROUND. The optimal treatment for elderly patients (defined as patients 70 years of age or older) with malignant gliomas (MG) remains controversial. Some physicians advocate withholding therapy following diagnosis based on the observation that elderly patients do not tolerate adjuvant radiotherapy. The availability of temozolomide (TMZ), a new alkylating agent with antiglioma efficacy, offers another potential therapeutic option for these patients. The drug can be administered orally at home with minimal morbidity. METHODS. The authors retrospectively reviewed a cohort of 86 consecutive elderly MG patients from three institutions, 32 of whom received monthly TMZ in lieu of radiation. RESULTS. Initial Karnofsky performance score was the only predictor of survival in this cohort. No difference in survival was noted between these two groups. Toxicity was minimal in the chemotherapy-treated group and a higher percentage of patients receiving chemotherapy died at home. CONCLUSIONS. The authors concluded that TMZ is as effective as irradiation as a treatment of elderly patients with MG. It is an alternative and, perhaps, a superior therapeutic option to irradiation, based on its ease of administration and low morbidity.

UR - http://www.scopus.com/inward/record.url?scp=0037403996&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037403996&partnerID=8YFLogxK

U2 - 10.1002/cncr.11323

DO - 10.1002/cncr.11323

M3 - Article

C2 - 12712481

AN - SCOPUS:0037403996

VL - 97

SP - 2262

EP - 2266

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 9

ER -